Skip to main content
Back
Close

COVID-19 Research Trials

Study Title: ACT 2 – Anti-Coronavirus Therapies (ACT) to prevent progression of COVID-19: Randomized trials

SRHC Principal Investigator: Dr. Carter Thorne

Aim: to evaluate anti-inflammatory and anti-thrombotic therapy to determine whether they prevent clinical progression of COVID-19 in inpatients.

Treatment:

Inpatients

  • Anti-inflammatory: colchicine vs. control
  • Antithrombotic: combination of ASA and rivaroxaban vs. control

Outpatients

  • Anti-inflammatory: colchicine vs. control
  • Antithrombotic: ASA vs. control

Study Population: COVID -19 positive inpatients & outpatients that meet all of the inclusion criteria and none of the exclusion as per the study

 

Study Title: Assessing the psychological, social, and economic impacts of an emerging pandemic (C19 Online Survey)

SRHC Principal Investigator: Janet Jeffrey, RN, PhD

Summary: To examine the psychological, social, and economic impacts of the COVID-19 pandemic at various stages of the outbreak. Special attention will be given to social isolation, as well as family and work related factors.

Study Population: All individuals who are at least 12 years of age

Link to Survey: COVID-19 Online Survey       

 

Study Title:  Risk of death or respiratory failure in patients with COVID-19 who received an ACE inhibitor, ARB, or NSAID: A Multicentre Cohort study [COVID-ACE/ARB/NSAID]

SRHC Principal Investigator: Dr. Yaariv Khayin

Summary: A retrospective study investigating the association between use of ACE inhibitors, ARBs, or NSAIDs with all-cause mortality, intensive care unit (ICU) admission or respiratory failure requiring mechanical ventilation among hospitalized patients with a confirmed diagnosis of COVID-19.

Study Population: COVID-19 positive adults 40 years and older

 

Study Title:  RAPID COVID COAG – Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic

SRHC Principal Investigator: Dr. Jai Jayakar

Aim: To determine the effect of therapeutic anticoagulation, with low molecular weight heparin (LMWH) or unfractionated heparin (UFH) (high dose nomogram), compared to standard care in hospitalized patients admitted for COVID-19 with an elevated D-dimer, on the composite outcome of ICU admission, non-invasive positive pressure ventilation, invasive mechanical ventilation or death at 28 days

Study Population:  COVID -19 positive inpatients that meet all of the inclusion criteria and none of the exclusion as per the study

 

Study Title: Exploring the Perspectives of Families of Pediatric Patients Who Have Eating Disorders on Medical Appointment Attendance and Refeeding during the COVID-19 Pandemic

SRHC Principal Investigator: Edigna Kusi Appiah RN, MN, NP-Pediatrics

Aim: To identify why patients have been keeping or not keeping medical appointments in the Eating Disorders Program during the COVID-19 pandemic; and to understand what factors that contribute to patients’ weight stabilization during the COVID-19 pandemic.

Study Population: Children and adolescent patients (pediatric population) who are 8-18 years of age and their parents.

 

Study Title: Virtual Family-Based Treatment (FBT) during a global pandemic: Exploring early treatment response and remission rates in a child and adolescent eating disorder sample

SRHC Principal Investigator: Jessica Pereira PhD, C. Psych

Aim: To determine if FBT (Family Based Treatment) being utilized in the Eating Disorders Program at Southlake Regional Health Centre can be effectively delivered using a virtual platform

Study Population: Child and adolescent patients and their families who have/will participate in virtual FBT compared to a matched-sample of participants who received FBT prior to COVID-19 restrictions.